{"denoms":[{"counts":[{"groupId":"BG000","value":"120"}],"units":"Participants"}],"groups":[{"description":"ClaPd therapy:\n\nDexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.\n\nPomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.\n\ndexamethasone: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle\n\nclarithromycin: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle\n\nPomalidomide: orally 4mg daily for days 1-21 of each 28 day cycle","id":"BG000","title":"All Patients"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"42","upperLimit":"87","value":"63"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"58"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"112"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"93"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6.4","upperLimit":"14.6","value":"10.4"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Hemoglobin","unitOfMeasure":"g/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"3","upperLimit":"15","value":"5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Range of Prior Therapies","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.2","upperLimit":"40.4","value":"35"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Beta-2 microglobulin at baseline (in mg/L)","unitOfMeasure":"mg/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"79","upperLimit":"1353","value":"170.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"lactage dehydrogenase at baseline (U/L)","unitOfMeasure":"u/l"}],"populationDescription":"121 subject signed consent; 1 subject was not considered to be evaluable and was not included in any analysis."}